RecruitingNot ApplicableNCT04532424

Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD

Sponsor

Stanford University

Enrollment

67 participants

Start Date

Jan 4, 2021

Study Type

INTERVENTIONAL

Conditions

Investigating the efficacy of a form of TMS called theta-burst stimulation for restricted and repetitive behavior in ASD.

Min Age: 12 YearsMax Age: 45 Years

Diagnosis of Autism Spectrum Disorder (ASD)
Meet criteria for Autism Spectrum Disorder (ASD) on clinical assessments (ADOS-2 or CARS if conducted remotely \& ADI-R)
Aged between 12-45 years old
Have a reliable informant who can complete relevant questionnaires
Have DARB scores which indicate high levels (50% or above) of RRB on one of the following domains: Insistence on Sameness, Obsessive Compulsive Behaviors, and Unusual Interests

Any contraindications for TMS e.g. history of seizures other than clear substance-induced/fever-induced seizures with neurologist note or normal clean EEG and no seizure in at least 12 months prior to enrollment.
Pregnancy.
Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.
Active substance use (<1 week) or intoxication verified by toxicology screen--of cocaine, amphetamines, benzodiazepines.
Showing symptoms of withdrawal from alcohol or benzodiazepines.
DSM-5 diagnosis of bipolar disorder or a psychotic disorder e.g. schizophrenia.
Significant sensory impairments such as blindness or deafness.
Current severe insomnia (must sleep a minimum of 4 hours the night before stimulation).
Not willing to cooperate with the TMS procedures.
Currently taking Clozapine or another medication that the PI determines increases the risk of TMS or may disrupt the efficacy.
A motor threshold that is too high to allow safe/tolerable treatment.
Conditions that increase the risk for COVID-19 (in accordance with university guidelines).

Interested in this trial?

Get notified about updates and connect with the research team.

DEVICETranscranial magnetic stimulation

Non-invasive brain stimulation technique that is FDA-approved for the treatment of refractory depression, OCD and migraine.

Stanford University

Stanford, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT04532424